Knight Therapeutics Inc. (KHTRF) — Earnings Call X-Ray
Our AI read all 29 of KHTRF's earnings calls (2016–2025) and answered the same battery of questions about each one. Every past call is free; the newest quarter unlocks with a free account.
Previous Call Grade
B+
Q4 2024
Calls Analyzed
29
2016–2025
Avg Candor
6.7/9
evasion 2.6/9
Call-by-call analysis
🔒 Q1 2025 earnings call
2025-05-11
NEWEST
Guidance: ■■■■■Demand: ■■■■■■
Margins: ■■■■Backlog: ■■■■
■ analysts, ■■ questionsexpected move ±■■%
Management ■■■■■■ guidance against ■■■■■■■■ demand and ■■■■■■■ margins. The delivery was ■■■■■■■■ and ■■■■ in specifics, with ■■■ questions left hanging.
🔒 The Q1 2025 call grade is ready
The full 37-point AI read of KHTRF's newest earnings call — grade, expected move, and every question answered — is free with an account.
Sign up free to unlock
B+
Q4 2024 earnings call
2025-03-20
move ±9.8%
Management held guidance steady against steady demand and contracting margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: stableMargins: contractingPricing: under pressureHeadcount: growing 6 analysts · 16 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up aheadHidden segment
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
C+
Q3 2024 earnings call
2024-11-09
move ±9%
Management held guidance steady against steady demand and contracting margins. The delivery was rich in specifics.
Guidance: maintainedDemand: stableMargins: contractingPricing: under pressureHeadcount: growing 3 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedDirection beats results
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
B
Q1 2024 earnings call
2024-05-11
move ±8.8%
Management held guidance steady against steady demand and contracting margins. The delivery was rich in specifics, relaxed under questioning.
Guidance: maintainedDemand: stableMargins: contractingPricing: under pressure 4 analysts · 7 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsedHidden segment
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
YES Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
C+
Q4 2023 earnings call
2024-03-21
move ±7.7%
Management held guidance steady against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: maintainedDemand: stableMargins: contractingPricing: under pressure 3 analysts · 8 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts⚑ Reads rehearsed
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
YES Does the call read rehearsed rather than lived?
A
Q3 2023 earnings call
2023-11-12
move ±10.2%
Management raised guidance against accelerating demand and expanding margins. The delivery was unusually candid, rich in specifics, relaxed under questioning.
Guidance: raisedDemand: acceleratingMargins: expandingPricing: stable 4 analysts · 9 questions
✓ Clean call✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Early product, fast growth
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
NO Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
YES Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
YES Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B+
Q2 2023 earnings call
2023-08-10
move ±14.9%
Management raised guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: stableMargins: contractingPricing: under pressureHeadcount: growing 3 analysts · 6 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
NO Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
NO Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
B+
Q1 2023 earnings call
2023-05-13
move ±9%
Management raised guidance against steady demand and contracting margins. The delivery was unusually candid, rich in specifics.
Guidance: raisedDemand: stableMargins: contractingPricing: under pressure 3 analysts · 8 questions
⚑ Critic ammunition✓ Skeptic reassured✓ Guidance underwritable✓ Resolves doubts✓ Volume step-up aheadHidden segment
All 20 questions our AI answered about this call
YES Would a skeptical short-seller find this call reassuring?
YES Would a careful investor underwrite management's guidance?
YES Is management's confidence proportionate to the evidence presented?
YES Does the call resolve more doubts than it creates?
YES Is there something a critic could fairly use against the company?
NO Is a claimed advantage dependent on scale they lack?
NO Does an obvious question remain unanswered?
NO Is a product early in its life but growing very fast?
NO Do they serve a small fraction of their addressable customers?
YES Is volume about to step up rather than grow gradually?
NO Are high fixed costs currently underutilised?
NO Is pricing recovering from a depressed level?
NO Do current results look bad while the direction looks better?
NO Are deferred revenue or customer prepayments growing?
NO Is consolidation happening among their peers?
NO Is a founder still running the company?
NO Does the final speaker sound like they are summarizing a finished story?
YES Is a fast-growing segment obscured by a declining one?
NO Does the CFO speak more than the CEO?
NO Does the call read rehearsed rather than lived?
Earlier calls
| Call | Date | Grade | Guidance | Demand | Margins | Candor | Evasion |
|---|
| Q4 2022 |
2023-03-23 |
B |
none | mixed | contracting |
7/9 |
2/9 |
| Q3 2022 |
2022-11-13 |
B+ |
raised | mixed | contracting |
7/9 |
2/9 |
| Q2 2022 |
2022-08-12 |
B+ |
maintained | mixed | expanding |
7/9 |
2/9 |
| Q1 2022 |
2022-05-12 |
C+ |
raised | accelerating | expanding |
6/9 |
4/9 |
| Q4 2021 |
2022-03-24 |
B |
maintained | mixed | expanding |
6/9 |
2/9 |
| Q3 2021 |
2021-11-12 |
B |
none | mixed | expanding |
7/9 |
2/9 |
| Q2 2021 |
2021-08-13 |
C+ |
none | mixed | expanding |
7/9 |
3/9 |
| Q1 2021 |
2021-05-14 |
B |
maintained | mixed | expanding |
7/9 |
2/9 |
| Q4 2020 |
2021-03-25 |
C |
none | mixed | contracting |
7/9 |
3/9 |
| Q3 2020 |
2020-11-13 |
F |
none | slowing | contracting |
6/9 |
4/9 |
| Q2 2020 |
2020-08-13 |
C |
none | slowing | contracting |
6/9 |
3/9 |
| Q1 2020 |
2020-06-26 |
C+ |
none | mixed | contracting |
7/9 |
2/9 |
| Q4 2019 |
2020-03-31 |
C+ |
none | stable | unclear |
7/9 |
2/9 |
| Q3 2019 |
2019-11-12 |
C |
none | stable | contracting |
7/9 |
2/9 |
| Q2 2019 |
2019-08-11 |
C |
none | stable | unclear |
6/9 |
3/9 |
| Q1 2019 |
2019-05-12 |
D |
none | stable | contracting |
6/9 |
0/9 |
| Q4 2018 |
2019-03-15 |
F |
none | stable | unclear |
6/9 |
3/9 |
| Q2 2018 |
2018-08-11 |
B |
none | mixed | contracting |
7/9 |
2/9 |
| Q2 2017 |
2017-08-10 |
D |
none | stable | contracting |
6/9 |
5/9 |
| Q1 2017 |
2017-05-11 |
C+ |
none | accelerating | unclear |
7/9 |
3/9 |
| Q4 2015 |
2016-03-24 |
B |
maintained | stable | unclear |
8/9 |
2/9 |
How to read this page
The grade is a transparent composite of call quality — candor, specificity, low evasion, low stress, whether the call resolves more doubts than it creates, and the guidance action — not a buy or sell signal. The expected move is a volatility estimate from the one signal that survived our out-of-sample tests: how a stock's own reaction and pre-call volatility predict the size (not direction) of its next move. Full detail, including everything that failed: methodology.
Companies with similar call quality
← KHRNF All “K” companies
KIADF →
Not investment advice. Artul.ai publishes AI-generated earnings-call quality grades and expected-volatility estimates — never buy or sell recommendations. We tested over 1,600 predictive hypotheses against 165,000 transcripts; the honest result, including what failed, is documented in our
methodology.